{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:49:55Z","timestamp":1786549795564,"version":"build-2736575974"},"reference-count":74,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-hrv260001-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Clinical trials in cardiovascular medicine aim to deliver high-quality evidence with greater efficiency, including smaller sample sizes and shorter timelines. The selection of sensitive and reliable end points is central to this goal. Right ventricular (RV) structure and function play a critical role in many cardiovascular conditions; however, RV-specific parameters remain underused and inconsistently applied in interventional clinical trials. In this article, the current and emerging role of RV-focused imaging and hemodynamic parameters as end points in clinical trials are explored and a comprehensive framework for their development, validation, and broader implementation is proposed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hrv260001-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>Across multiple disease domains, RV-focused parameters derived from echocardiography, cardiac magnetic resonance imaging, computed tomography, and right-sided heart catheterization demonstrate potential value in assessing the therapeutic effects of new medicines or devices across a wide range of conditions including heart failure, cardiomyopathies, valve diseases, pulmonary hypertension, and congenital heart conditions. However, their use is inconsistent, and feasibility challenges are common, particularly in multicenter clinical trial settings. Key limitations include variability in imaging acquisition, incomplete data capture, lack of standardized protocols, and insufficient validation linking short-term RV changes to long-term clinical outcomes. Emerging tools such as artificial intelligence may improve reproducibility and efficiency, while collaborative, multidisciplinary efforts are essential for advancing end-point development.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hrv260001-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>RV-specific end points hold substantial promise for enhancing the sensitivity and mechanistic insight of clinical trials but remain inadequately integrated into current practice. Optimal end-point selection requires balancing clinical relevance, analytical validity, and operational feasibility, with consideration of disease-specific pathophysiology and trial design. Standardization of acquisition, validation of clinically meaningful changes, and centralized data analysis are important next steps. Broader adoption of robust RV metrics supported by technological innovation and cross-sector collaboration has the potential to improve trial efficiency, accelerate therapeutic development, and ultimately enhance patient outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.2053","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:32:27Z","timestamp":1782315147000},"page":"772","source":"Crossref","is-referenced-by-count":0,"title":["Right Ventricular Metrics as End Points in Clinical Trials"],"prefix":"10.1001","volume":"11","author":[{"given":"Elena","family":"Surkova","sequence":"first","affiliation":[{"name":"Translational Science and Clinical Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom"},{"name":"Royal Brompton and Harefield Hospitals, Guy\u2019s and St Thomas\u2019 NHS Foundation Trust, London, United Kingdom"},{"name":"National Heart and Lung Institute, Imperial College, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e1lint","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kempton","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex Pui-Wai","family":"Lee","sequence":"additional","affiliation":[{"name":"Li Ka Shing Institute of Health Sciences, the Chinese University of Hong Kong, Shat Tin, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JoAnn","family":"Lindenfeld","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao A. C.","family":"Lima","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Rosenkranz","sequence":"additional","affiliation":[{"name":"Department of Cardiology\u2013Internal Medicine III, Heart Center, University Hospital Cologne, Cologne, Germany"},{"name":"Cologne Cardiovascular Research Center, Heart Center, University Hospital Cologne, Cologne, Germany"},{"name":"Center for Molecular Medicine Cologne, Faculty of Medicine, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry A.","family":"Borlaug","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Hausleiter","sequence":"additional","affiliation":[{"name":"Medizinische Klinik und Poliklinik I, LMU Klinikum, LMU M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Burkhoff","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Foundation, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denisa","family":"Muraru","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Istituto Auxologico Italiano, IRCCS, Milan, Italy"},{"name":"Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leon","sequence":"additional","affiliation":[{"name":"Cardiovascular Research Foundation, New York, New York"},{"name":"Irving Medical Center, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"Hahn","sequence":"additional","affiliation":[{"name":"Irving Medical Center, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attila","family":"Kov\u00e1cs","sequence":"additional","affiliation":[{"name":"Heart and Vascular Center, Semmelweis University, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"hrv260001r1","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2011.175","article-title":"A historical perspective on clinical trials innovation and leadership: where have the academics gone?","volume":"305","author":"DeMets","year":"2011","journal-title":"JAMA"},{"issue":"23","key":"hrv260001r2","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1161\/CIRCULATIONAHA.123.066982","article-title":"The future of clinical trials.","volume":"149","author":"Zannad","year":"2024","journal-title":"Circulation"},{"issue":"43","key":"hrv260001r3","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1093\/eurheartj\/ehad653","article-title":"Tricuspid valve academic research consortium definitions for tricuspid regurgitation and trial end points.","volume":"44","author":"Hahn","year":"2023","journal-title":"Eur Heart J"},{"issue":"2","key":"hrv260001r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocmr.2024.101118","article-title":"Impact of cardiovascular magnetic resonance-derived right ventricular ejection fraction on adverse outcomes: a robust bayesian model-averaged meta-analysis.","volume":"26","author":"Kitano","year":"2024","journal-title":"J Cardiovasc Magn Reson"},{"issue":"11","key":"hrv260001r5","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.echo.2019.06.009","article-title":"Relative prognostic importance of left and right ventricular ejection fraction in patients with cardiac diseases.","volume":"32","author":"Surkova","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hrv260001r6","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jcmg.2016.12.003","article-title":"Use of imaging endpoints in clinical trials.","volume":"10","author":"Gillam","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"138","key":"hrv260001r7","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1183\/16000617.0062-2015","article-title":"Right heart catheterization: best practice and pitfalls in pulmonary hypertension.","volume":"24","author":"Rosenkranz","year":"2015","journal-title":"Eur Respir Rev"},{"issue":"3","key":"hrv260001r8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.chest.2023.09.029","article-title":"Prospective evaluation of venous excess ultrasound for estimation of venous congestion.","volume":"165","author":"Longino","year":"2024","journal-title":"Chest"},{"issue":"1","key":"hrv260001r9","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13054-025-05806-9","article-title":"VExUS and right ventricular to pulmonary artery uncoupling.","volume":"30","author":"Rola","year":"2025","journal-title":"Crit Care"},{"issue":"6","key":"hrv260001r10","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1161\/CIRCHEARTFAILURE.115.002249","article-title":"Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone.","volume":"8","author":"Shah","year":"2015","journal-title":"Circ Heart Fail"},{"issue":"17","key":"hrv260001r11","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1056\/NEJMoa1900486","article-title":"A fully magnetically levitated left ventricular assist device\u2014final report.","volume":"380","author":"Mehra","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"hrv260001r12","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1056\/NEJMoa1602954","article-title":"Intrapericardial left ventricular assist device for advanced heart failure.","volume":"376","author":"Rogers","year":"2017","journal-title":"N Engl J Med"},{"issue":"7","key":"hrv260001r13","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/S2213-2600(19)30091-8","article-title":"Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicenter, randomized, double-blind, placebo-controlled, phase 4 trial.","volume":"7","author":"Sitbon","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"15","key":"hrv260001r14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1093\/eurheartj\/ehx025","article-title":"SERAPHIN hemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on hemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.","volume":"38","author":"Gali\u00e8","year":"2017","journal-title":"Eur Heart J"},{"issue":"4","key":"hrv260001r15","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1056\/NEJMoa1209655","article-title":"Riociguat for the treatment of pulmonary arterial hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"14","key":"hrv260001r16","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.jacc.2021.07.057","article-title":"Three- vs 2-drug therapy for patients with newly diagnosed pulmonary arterial hypertension.","volume":"78","author":"Chin","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"hrv260001r17","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1056\/NEJMoa2415160","article-title":"Sotatercept in patients with pulmonary arterial hypertension at high risk for death.","volume":"392","author":"Humbert","year":"2025","journal-title":"N Engl J Med"},{"issue":"4","key":"hrv260001r18","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S2213-2600(14)70013-X","article-title":"Tadalafil in patients with chronic obstructive pulmonary disease: a randomized, double-blind, parallel-group, placebo-controlled trial.","volume":"2","author":"Goudie","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"4","key":"hrv260001r19","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.","volume":"369","author":"Ghofrani","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"hrv260001r20","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(24)00027-4","article-title":"Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicenter, phase 2, randomized, double-blind, placebo-controlled study.","volume":"12","author":"Ghofrani","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"14","key":"hrv260001r21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jcin.2018.04.008","article-title":"A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial.","volume":"11","author":"Tapson","year":"2018","journal-title":"JACC Cardiovasc Interv"},{"issue":"12","key":"hrv260001r22","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jamacardio.2022.3591","article-title":"Catheter-directed thrombolysis vs anticoagulation in patients with acute intermediate-high-risk pulmonary embolism: the CANARY randomized clinical trial.","volume":"7","author":"Sadeghipour","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"4","key":"hrv260001r23","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/CIRCULATIONAHA.113.005544","article-title":"Randomized, controlled trial of ultrasound-assisted catheter-directed thrombolysis for acute intermediate-risk pulmonary embolism.","volume":"129","author":"Kucher","year":"2014","journal-title":"Circulation"},{"issue":"12","key":"hrv260001r24","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jcin.2021.04.049","article-title":"Randomized trial comparing standard versus ultrasound-assisted thrombolysis for submassive pulmonary embolism: the SUNSET SPE trial.","volume":"14","author":"Avgerinos","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"hrv260001r25","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.chest.2023.09.007","article-title":"Oxygen therapy in patients with intermediate-risk acute pulmonary embolism: a randomized trial.","volume":"165","author":"Barrios","year":"2024","journal-title":"Chest"},{"issue":"5","key":"hrv260001r26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1161\/CIRCULATIONAHA.124.072364","article-title":"Large-bore mechanical thrombectomy vs catheter-directed thrombolysis in the management of intermediate-risk pulmonary embolism: primary results of the PEERLESS randomized controlled trial.","volume":"151","author":"Jaber","year":"2025","journal-title":"Circulation"},{"issue":"12","key":"hrv260001r27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/j.jcmg.2024.05.014","article-title":"Dapagliflozin effects on cardiac deformation in heart failure and secondary clinical outcome.","volume":"17","author":"Pastore","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"issue":"6","key":"hrv260001r28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.echo.2018.01.008","article-title":"Right ventricular longitudinal strain reproducibility using vendor-dependent and vendor-independent software.","volume":"31","author":"Il\u2019Giovine","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"hrv260001r29","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/echo.14218","article-title":"Variability of right ventricular global and segmental longitudinal strain measurements.","volume":"36","author":"Mirea","year":"2019","journal-title":"Echocardiography"},{"issue":"4","key":"hrv260001r30","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.echo.2018.11.014","article-title":"Comparison between 4-chamber and right ventricular-focused views for the quantitative evaluation of right ventricular size and function.","volume":"32","author":"Genovese","year":"2019","journal-title":"J Am Soc Echocardiogr"},{"issue":"15","key":"hrv260001r31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/eurheartj\/ehw593","article-title":"Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the Soluble Guanylate Cyclase Stimulator in Heart Failure Patients with PRESERVED EF (SOCRATES-PRESERVED) study.","volume":"38","author":"Pieske","year":"2017","journal-title":"Eur Heart J"},{"issue":"5","key":"hrv260001r32","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","article-title":"Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.","volume":"37","author":"Solomon","year":"2016","journal-title":"Eur Heart J"},{"issue":"17","key":"hrv260001r33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1016\/j.jacc.2024.08.021","article-title":"Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure.","volume":"84","author":"Solomon","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"hrv260001r34","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1001\/jamacardio.2024.1914","article-title":"Dapagliflozin and right ventricular-pulmonary vascular interaction in heart failure with preserved ejection fraction: a secondary analysis of a randomized clinical trial.","volume":"9","author":"Reddy","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"9","key":"hrv260001r35","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1016\/j.healun.2015.06.015","article-title":"Right ventricular failure after left ventricular assist devices.","volume":"34","author":"Lampert","year":"2015","journal-title":"J Heart Lung Transplant"},{"issue":"19","key":"hrv260001r36","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","article-title":"Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 128 results from VALOR-HCM.","volume":"151","author":"Desai","year":"2025","journal-title":"Circulation"},{"issue":"19","key":"hrv260001r37","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/j.jacc.2024.08.002","article-title":"Impact of aficamten on echocardiographic cardiac structure and function in symptomatic obstructive hypertrophic cardiomyopathy.","volume":"84","author":"Hegde","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"hrv260001r38","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial.","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"issue":"6","key":"hrv260001r39","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jacc.2025.06.022","article-title":"Effects of vutrisiran on cardiac function and outcomes in patients with transthyretin amyloidosis with cardiomyopathy.","volume":"86","author":"Jering","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hrv260001r40","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1002\/ejhf.2661","article-title":"Right ventricular dysfunction predicts outcome after transcatheter mitral valve repair for primary mitral valve regurgitation.","volume":"24","author":"Doldi","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"hrv260001r41","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/j.jcmg.2020.12.015","article-title":"Impact of right ventricular dysfunction on outcomes after transcatheter edge-to-edge repair for secondary mitral regurgitation.","volume":"14","author":"Karam","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"issue":"20","key":"hrv260001r42","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1056\/NEJMoa2300525","article-title":"Transcatheter repair for patients with tricuspid regurgitation.","volume":"388","author":"Sorajja","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"hrv260001r43","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.122.012888","article-title":"Two-year outcomes for tricuspid repair with a transcatheter edge-to-edge valve repair from the transatlantic TRILUMINATE trial.","volume":"16","author":"von Bardeleben","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"issue":"23","key":"hrv260001r44","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1016\/j.jcin.2024.09.069","article-title":"Biphasic right ventricular reverse remodeling following tricuspid valve transcatheter edge-to-edge repair.","volume":"17","author":"Stolz","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"2","key":"hrv260001r45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa2401918","article-title":"Transcatheter valve replacement in severe tricuspid regurgitation.","volume":"392","author":"Hahn","year":"2025","journal-title":"N Engl J Med"},{"issue":"23","key":"hrv260001r46","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/j.jcin.2024.10.007","article-title":"Midterm outcomes of K-Clip transcatheter tricuspid annuloplasty system in patients with severe functional tricuspid regurgitation.","volume":"17","author":"Xu","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"5","key":"hrv260001r47","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.4244\/EIJ-D-24-00591","article-title":"Transcatheter annuloplasty with the K-Clip system for tricuspid regurgitation: 1-year results from the Tristar study.","volume":"21","author":"Zhang","year":"2025","journal-title":"EuroIntervention"},{"issue":"10","key":"hrv260001r48","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.jcin.2024.12.030","article-title":"Transcatheter tricuspid valve replacement with the novel system: 1-year outcomes from the TRAVEL study.","volume":"18","author":"Pan","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"issue":"7","key":"hrv260001r49","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jacc.2024.05.006","article-title":"Real-world 1-year results of tricuspid edge-to-edge repair from the BRIGHT Study.","volume":"84","author":"Lurz","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"hrv260001r50","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1002\/ejhf.3274","article-title":"Residual tricuspid regurgitation after tricuspid transcatheter edge-to-edge repair: insights into the EUROTR registry.","volume":"26","author":"Stolz","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"122","key":"hrv260001r51","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1183\/09059180.00006711","article-title":"Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease.","volume":"20","author":"Howard","year":"2011","journal-title":"Eur Respir Rev"},{"issue":"10","key":"hrv260001r52","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/eurheartj\/ehu035","article-title":"Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension.","volume":"36","author":"Shah","year":"2015","journal-title":"Eur Heart J"},{"issue":"3","key":"hrv260001r53","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01107-2023","article-title":"Effects of sotatercept on hemodynamics and right heart function: analysis of the STELLAR trial.","volume":"62","author":"Souza","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"hrv260001r54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension.","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"issue":"2","key":"hrv260001r55","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jcmg.2021.07.027","article-title":"The REPAIR study: effects of macitentan on RV structure and function in pulmonary arterial hypertension.","volume":"15","author":"Vonk Noordegraaf","year":"2022","journal-title":"JACC Cardiovasc Imaging"},{"issue":"4","key":"hrv260001r56","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S2213-2600(24)00425-9","article-title":"Future treatment paradigms in pulmonary arterial hypertension: a personal view from physicians, health authorities, and patients.","volume":"13","author":"Rahaghi","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"4","key":"hrv260001r57","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS).","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"3","key":"hrv260001r58","doi-asserted-by":"publisher","DOI":"10.1111\/echo.70107","article-title":"Diagnostic and prognostic value of RV strain defined as RV\/LV ratio on chest CT in acute pulmonary embolism: a systematic review.","volume":"42","author":"Hanmandlu","year":"2025","journal-title":"Echocardiography"},{"issue":"10","key":"hrv260001r59","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1007\/s00392-022-02138-4","article-title":"Recovery of right ventricular function after intermediate-risk pulmonary embolism: results from the multicenter Pulmonary Embolism International Trial (PEITHO)-2.","volume":"112","author":"Mavromanoli","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"hrv260001r60","doi-asserted-by":"publisher","DOI":"10.1183\/20734735.0100-2024","article-title":"The latest in the management of pulmonary embolism.","volume":"21","author":"Yuriditsky","year":"2025","journal-title":"Breathe (Sheff)"},{"issue":"7","key":"hrv260001r61","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1093\/ehjci\/jeaf105","article-title":"Three-dimensional echocardiography in adults with congenital heart disease: a scientific statement of the European Society of Cardiology Working Group on Adult Congenital Heart Disease and the European Association of Cardiovascular Imaging of the European Society of Cardiology.","volume":"26","author":"Surkova","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"14","key":"hrv260001r62","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.117.031438","article-title":"Effect of losartan on right ventricular dysfunction: results from the double-blind, randomized REDEFINE trial (Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-Angiotensin-Aldosterone System) in adults with repaired tetralogy of Fallot.","volume":"137","author":"Bokma","year":"2018","journal-title":"Circulation"},{"issue":"3","key":"hrv260001r63","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ijcard.2010.09.057","article-title":"Randomized trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace Inhibitors for Potential Prevention of the Deleterious Effects of Pulmonary Regurgitation in Adults With Repaired Tetralogy of Fallot).","volume":"154","author":"Babu-Narayan","year":"2012","journal-title":"Int J Cardiol"},{"issue":"11","key":"hrv260001r64","doi-asserted-by":"publisher","first-page":"S201","DOI":"10.1161\/CIRCULATIONAHA.110.951178","article-title":"Randomized trial of pulmonary valve replacement with and without right ventricular remodeling surgery.","volume":"122","author":"Geva","year":"2010","journal-title":"Circulation"},{"issue":"7","key":"hrv260001r65","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/ejhf.2924","article-title":"Effect of phosphodiesterase-5 inhibition on systemic right ventricular size and function: a multicenter, double-blind, randomized, placebo-controlled trial: SERVE.","volume":"25","author":"Greutmann","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"hrv260001r66","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1161\/CIRCULATIONAHA.112.135392","article-title":"Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial.","volume":"127","author":"van der Bom","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"hrv260001r67","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.jchf.2024.01.006","article-title":"Dapagliflozin in patients with a failing systemic right ventricle: results from the DAPA-SERVE trial.","volume":"12","author":"Fusco","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"45","key":"hrv260001r68","doi-asserted-by":"publisher","first-page":"4738","DOI":"10.1093\/eurheartj\/ehad510","article-title":"Cardiac magnetic resonance biomarkers as surrogate end points in cardiovascular trials for myocardial diseases.","volume":"44","author":"Benz","year":"2023","journal-title":"Eur Heart J"},{"issue":"1","key":"hrv260001r69","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1038\/s41569-025-01180-9","article-title":"Challenges and opportunities in assessing right ventricular structure and function: a roadmap for standardization, clinical implementation and research.","volume":"23","author":"Kovacs","year":"2026","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"hrv260001r71","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.echo.2024.04.005","article-title":"Significant disagreement between conventional parameters and 3D echocardiography-derived ejection fraction in the detection of right ventricular systolic dysfunction and its association with outcomes.","volume":"37","author":"Tolvaj","year":"2024","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hrv260001r72","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the echocardiographic assessment of the right heart in adults and special considerations in pulmonary hypertension: recommendations from the American Society of Echocardiography.","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J Am Soc Echocardiogr"},{"issue":"4","key":"hrv260001r73","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1001\/jama.2025.8731","article-title":"Complete AI-enabled echocardiography interpretation with multitask deep learning.","volume":"334","author":"Holste","year":"2025","journal-title":"JAMA"},{"issue":"8","key":"hrv260001r74","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/ehjci\/jeaf147","article-title":"Deep learning-enabled echocardiographic assessment of biventricular ejection fractions: the dual-task QUEST-EF model.","volume":"26","author":"Szij\u00e1rt\u00f3","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"hrv260001r70","unstructured":"US Food and Drug Administration. Table of surrogate end points that were the basis of drug approval or licensure. Accessed October 22, 2025. https:\/\/www.fda.gov\/drugs\/development-resources\/table-surrogate-endpoints-were-basis-drug-approval-or-licensure"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2850861\/jamacardiology_surkova_2026_rv_260001_1786123765.12148.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:46Z","timestamp":1786546846000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2850861"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":74,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.2053","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}